Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BECTON, DICKINSON AND COMPANY

(BDX)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Becton Dickinson and : BD Breaks Ground on High-Tech Manufacturing Facility in Zaragoza, Spain to Support Growth of Pre-Filled Drug Delivery

11/16/2021 | 06:06am EST

FRANKLIN LAKES, N.J. (November 16, 2021) - BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, broke ground on a €165 million ($200 million USD) manufacturing facility in the city of Zaragoza, located in the Aragon region of Spain.

The new site, which will initially encompass 8,000 square meters (86,000 square feet), is estimated to open in late 2023. BD is beginning its recruitment process to fill key positions supporting the design and set-up of this site, including engineers, technicians, and other key support staff. Open roles can be found at https://emea.jobs.bd.com/location/spain-jobs/28892/2510769/2.

"These roles will be on the front lines of building a sustainable, state-of-the-art and fully digital site incorporating the latest in intelligent and autonomous solutions," said Thibault Naegelen, program director for BD's Zaragoza facility. "We look forward to building a team in Zaragoza that helps BD meet its mission of advancing the world of health by supplying our European customers with devices that enhance drug delivery."

BD's Zaragoza team will produce drug delivery devices, primarily for biopharmaceutical companies that supply the European market with drugs in pre-fillable syringes such as vaccines and other biologic drugs. The new plant will add needed capacity to support major vaccination campaigns going forward, such as the one currently taking place for the COVID-19 pandemic.

"Pre-fillable drug systems are a known factor in helping health care providers effectively, reliably and consistently administer drug therapies," said Eric Borin, worldwide president of BD Pharmaceutical Systems. "Today, more than 70 percent of the top 100 biopharmaceutical companies rely on BD pre-fillable syringes. This groundbreaking marks an important milestone in our ability to extend manufacturing capacity for our customers as they continue to grow their vaccine and biologic drug pipelines."

BD will also be hiring operators and production staff to oversee the production lines closer to the site's opening date in 2023. The site will meet high sustainability and eco-efficiency standards. By 2030, the site is expected to employ up to 600 people with an area of 30,000 square meters (323,000 square feet).

The new site is part of the $1.2 billion, four-year USD investment that was announced in late 2020 to expand and upgrade BD's manufacturing capacity and technology for pre-fillable syringes and advanced drug delivery systems as part of the company's 2025 growth strategy. The Zaragoza facility will mark BD's fourth facility in Spain, where it currently has three production plants employing approximately 1,500 employees: San Agustín de Guadalix, Fraga and Almaraz.

About BD
BD is one of the largest global medical technology companies in the world and is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. The company supports the heroes on the frontlines of health care by developing innovative technology, services and solutions that help advance both clinical therapy for patients and clinical process for health care providers. BD and its 70,000 employees have a passion and commitment to help enhance the safety and efficiency of clinicians' care delivery process, enable laboratory scientists to accurately detect disease and advance researchers' capabilities to develop the next generation of diagnostics and therapeutics. BD has a presence in virtually every country and partners with organizations around the world to address some of the most challenging global health issues. By working in close collaboration with customers, BD can help enhance outcomes, lower costs, increase efficiencies, improve safety and expand access to health care. For more information on BD, please visit bd.com or connect with us on LinkedIn at www.linkedin.com/company/bd1/ and Twitter @BDandCo.

Contacts:

Media:

Investors:

Trey Hollern

Nadia Goncalves

BD Public Relations

BD Investor Relations

862.284.8629

201.847.5934

trey.hollern@bd.com

nadia.goncalves@bd.com

Disclaimer

BD - Becton, Dickinson and Company published this content on 16 November 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 16 November 2021 11:05:02 UTC.


ę Publicnow 2021
All news about BECTON, DICKINSON AND COMPANY
01/20BD Innovation Profiled in Cover Story of 'Science' Demonstrates Landmark Advancement in..
PR
01/12BD Named One of America's Most Just Companies in Annual JUST 100 Ranking
AQ
01/11BD, Pfizer, Wellcome Collaborate to Improve Global Hospital Antimicrobial Stewardship P..
PR
01/11Becton, Dickinson and Company and Pfizer Inc Collaborates to Improve Global Hospital An..
CI
01/11US to Require Insurers to Pay for At-Home COVID-19 Tests
MT
01/10BD Introduces Smart Connected Robotics to Automate Microbial Identification
AQ
01/07Becton, Dickinson, and Co. Gets US FDA 510(k) Clearance for Bacterial Identification Te..
MT
01/07BD Introduces Smart Connected Robotics to Automate Microbial Identification
PR
01/07Becton, Dickinson and Company Receives 510(K) Clearance from the U.S. Food and Drug Adm..
CI
01/06BD Announces Change to Virtual 2022 Annual Meeting of Shareholders
PR
More news
Analyst Recommendations on BECTON, DICKINSON AND COMPANY
More recommendations
Financials (USD)
Sales 2022 19 459 M - -
Net income 2022 2 337 M - -
Net Debt 2022 12 756 M - -
P/E ratio 2022 33,5x
Yield 2022 1,43%
Capitalization 75 243 M 75 243 M -
EV / Sales 2022 4,52x
EV / Sales 2023 4,22x
Nbr of Employees 75 000
Free-Float 77,4%
Chart BECTON, DICKINSON AND COMPANY
Duration : Period :
Becton, Dickinson and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends BECTON, DICKINSON AND COMPANY
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 16
Last Close Price 263,97 $
Average target price 272,62 $
Spread / Average Target 3,28%
EPS Revisions
Managers and Directors
Thomas E. Polen Chairman, President & Chief Executive Officer
Chris DelOrefice Chief Financial Officer & Executive Vice President
William R. Sigmund Chief Medical Officer & Executive Vice President
Jerry Flasz Chief Information Officer & EVP-Global Services
Elizabeth McCombs Chief Technology Officer & Executive VP
Sector and Competitors
1st jan.Capi. (M$)
BECTON, DICKINSON AND COMPANY4.93%75 243
ABBOTT LABORATORIES-11.39%213 874
MEDTRONIC PLC2.57%142 671
HOYA CORPORATION-10.96%49 292
BAXTER INTERNATIONAL INC.0.17%43 055
DEXCOM, INC.-19.05%42 126